Drug Profile
Trastuzumab biosimilar - Axxo
Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator AXXO
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown HER2 positive breast cancer
Most Recent Events
- 24 Sep 2013 Investigation in HER2-positive-breast-cancer in Germany (IV)